Journal Mobile Options
Table of Contents
Vol. 28, No. 2, 2005
Issue release date: 2005
Kidney Blood Press Res 2005;28:111–116

Comparison of the Effects of Quinapril and Losartan on Carotid Artery Intima-Media Thickness in Patients with Mild-to-Moderate Arterial Hypertension

Uchiyama-Tanaka Y. · Mori Y. · Kishimoto N. · Fukui M. · Nose A. · Kijima Y. · Yamahara H. · Hasegawa T. · Kosaki A. · Matsubara H. · Iwasaka T.
aDepartment of Medicine II, Kansai Medical University, Osaka and bDepartment of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Ultrasonographic evidence of increased carotid intima-media thickness (IMT) is known to be associated with generalized atherosclerosis. Therapeutic blockade of the renin-angiotensin system (RAS) with angiotensin-converting enzyme (ACE) inhibitors reportedly reduces carotid IMT in humans. However, there has been no head-to-head comparison of the effects of ACE inhibitor and angiotensin receptor blocker (ARB), a newer type of RAS inhibitor, on carotid IMT. Methods: 57 hypertensive patients were randomly assigned to treatment with one of two antihypertensive drugs: ACE inhibitor (quinapril; n = 25, group Q) or ARB (losartan; n = 18, group L). Results: After 1 year of treatment, a similar decrease in mean blood pressure was observed in all groups. Carotid IMT was decreased significantly in group Q (10% decrease, p < 0.05) but did not change in group L. There were no significant changes in other atherosclerotic factors between these two groups. Conclusion: Our findings suggest that the antiatherosclerotic effect of quinapril is more potent than that of losartan in hypertensive patients. This effect appears unrelated to the drug’s antihypertensive action or to traditional atherosclerotic factors.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Kannel WB: Hypertension as a risk factor for cardiac events: Epidemiologic results of long-term studies. J Cardiovasc Pharmacol 1993;21(suppl 2):27–37.
  2. Jacoby DS, Rader DJ: Renin-angiotensin system and atherothrombotic disease: From genes to treatment. Arch Intern Med 2003;163:1155–1164.
  3. Unger T: The role of the renin-angiotensin system in the development of cardiovascular disease Am J Cardiol 2002;89(suppl):3A–10A.
  4. Horiuchi M, Hamai M, Cui TX, Iwai M, Minokoshi Y: Cross-talk between angiotensin II type 1 and type 2 receptors: Cellular mechanism of angiotensin type 2 receptor-mediated cell growth inhibition. Hypertens Res 1999;22:67–74.
  5. Grobbee DE, Bots ML: Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 1994;263:567–573.
  6. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Eng J Med 1999;340:14–22.
  7. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension: Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001;24:613–634.
  8. Shibasaki Y, Mori Y, Tsutumi Y, Masaki H, Sakamoto K, Murasawa S, Maruyama K, Moriguchi Y, Tanaka Y, Iwasaka T, Inada M, Matsubara H: Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure. Clin Nephrol 1999;51:83–91.
  9. Wofford JL, Kahl FR, Howard GR, McKinney WM, Toole JF, Crouse JR 3rd: Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler Thromb 1991;11:1786–1794.
  10. Persson J, Stavenow L, Wikstrand J, Israelsson B, Formgren J, Berglund G: Noninvasive quantification of atherosclerotic lesions. Reproducibility of ultrasonographic measurements of arterial wall thickness and plaque size. Arterioscler Thromb 1992;12:261–266.
  11. Hornig B, Kohler C, Drexler H: Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95:1115–1118.
  12. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxide activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916–1923.
  13. Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M, Baumgartner HR: Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186–188.
  14. Campbell JH, Fennessy P, Campbell GR: Effect of perindopril on the development of atherosclerosis in the cholesterol-fed rabbit. Clin Exp Pharmacol Physiol Suppl 1992;19:13–17.
  15. Mayet J, Stanton AV, Sinclair AM, MacKay J, ShahiM, FoaleRA, NicolaidesA, PoulterNR, Sever PS, ThomSA, Hughes AD: The effects of antihypertensive therapy on carotid vascular structure in man. Cardiovasc Res 1995;30:147–152.
  16. Lonn EM, Yusuf S, Dzavik V, Doris CI, Yi Q, Smith S, Cox AM, Bosch J, Riley WA, Teo KK: Effects of ramipril and vitamin E on atherosclerosis: The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103:919–925.
  17. Hosomi N, Mizushige K, Ohyama H, Takahashi T, Kitadai M, Hatanaka Y, Matsuo H, Kohno M, Koziol JA: Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 2001;32:1539–1545.
  18. Ghiadoni L, Taddei S, Virdis A, Sudano I, Di Legge V, Meola M, Di Venanzio L, Salvetti A: Endothelial function and common carotid artery wall thickening in patients with essential hypertension. Hypertension 1998;32:25–32.
  19. Carallo C, Irace C, Pujia A, De Franceschi MS, Crescenzo A, Motti C, Cortese C, Mattioli PL, Gnasso A: Evaluation of common carotid hemodynamic forces. Relations with wall thickening. Hypertension 1999;34:217–221.
  20. Mancini GB, Henry GC, Macaya C, O’Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996;94:258–265.
  21. Anderson TJ, Elstein E, Haber K, Charbonneau F: Comparative study of ACE inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF Study). J Am Coll Cardiol 2000;35:60–66.
  22. Fabris B, Chen BZ, Pupic V, Perich R, Johnston CL: Inhibition of angiotensin-converting enzyme in plasma and tissue. J Cardiovasc Pharmacol 1990;15(suppl 2):6–13.

    External Resources

  23. Fabris B, Jackson B, Cubela R, Mendelsohn FA, Johnston CI: Angiotensin converting enzyme in the rat heart: Studies of its inhibition in vitro and ex vivo. Clin Exp Pharmacol Physiol 1989;16:309–313.
  24. Tsikouris JP, Suarez JA, Meyerrose GE, Ziska M, Fike D, Smith J: Questioning a class effect: Does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction? J Clin Pharmacol 2004;44:150–157.
  25. Lyons D, Webster J, Benjamin N: Effect of enalapril and quinapril on forearm vascular ACE in man. Eur J Clin Pharmacol 1997;51:373–378.
  26. Rajzer M, Klocek M, Kawecka-Jaszcz K: Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. Am J Hypertens 2003;16:439–444.
  27. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T: Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999;104:925–935.
  28. Benetos A, Gautier S, Lafleche A, Topouchian J, Frangin G, Girerd X, Sissmann J, Safar ME: Blockade of angiotensin II type 1 receptors: Effect on carotid and radial artery structure and function in hypertensive humans. J Vasc Res 2000;37:8–15.
  29. Ludwig M, Stapff M, Ribeiro A, Fritschka E, Tholl U, Smith RD, Stumpe KO: Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: Results of a two-year, double-blind, randomized, controlled study. Clin Ther 2002;24:1175–1193.
  30. Matsubara H: Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998;83:1182–1191.
  31. Vaughan DE: Angiotensin and vascular fibrinolytic balance. Am J Hypertens 2002;15:3S–8S.
  32. Willinek WA, Ludwig M, Lennarz M, Holler T, Stumpe KO: High-normal serum homocysteine concentrations are associated with an increased risk of early atherosclerotic carotid artery wall lesions in healthy subjects. J Hypertens 2000;18:425–430.
  33. Ohkuma T, Minagawa T, Takeda N, Ohno M, Oda H, Ohashi H: C-reactive protein, lipoprotein (a), homocysteine, and male sex contribute to carotid atherosclerosis in peritoneal dialysis patients. Am J Kidney Dis 2003;42:355–361.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50